(Q35778576)

10 August 2017

1 reference

title

Immunotherapeutic strategies for malignant glioma (English)

1 reference

10 August 2017

1 reference

Robert A Fenstermaker

series ordinal

1

1 reference

10 August 2017

Michael J Ciesielski

series ordinal

2

1 reference

10 August 2017

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

11

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

181-191

1 reference

10 August 2017

cites work

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Increasing incidence of primary malignant brain tumors: influence of diagnostic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Poor-prognosis high-grade gliomas: evolving an evidence-based standard of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Treatment of malignant glioma: a problem beyond the margins of resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Immunotherapy of metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Role of cervical lymph nodes in the systemic humoral immune response to human serum albumin microinfused into rat cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Cervical lymph nodes play the role of regional lymph nodes in brain tumour immunity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Pathways of fluid drainage from the brain--morphological aspects and immunological significance in rat and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Relationship of lymphocyte invasion and survival of brain tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Expression of Fas ligand by microglia: possible role in glioma immune evasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Site-specific immune response to implanted gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Immune defects observed in patients with primary malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Tenascin distribution in human brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Expression of the SART1 tumor rejection antigen in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Expression of the tumor-rejection antigen SART1 in brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus calmette-guerin cell-wall preparation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Systemic T cell adoptive immunotherapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

The generation of anti-tumoral cells using dentritic cells from the peripheral bloood of patients with malignant brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Structural alterations of the epidermal growth factor receptor gene in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Tandem duplication of the epidermal growth factor receptor tyrosine kinase and calcium internalization domains in A-172 glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

EGF mutant receptor vIII as a molecular target in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Interleukin-13 receptor as a unique target for anti-glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Role of an anti-epidermal growth factor receptor in treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

A new antibody recognizing the vIII mutation of human epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

Expression of survivin in primary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

AV.TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100306

10.1177/107327480401100306

21 January 2018

Identifiers

DOI

0 references

1 reference